CELLERON THERAPEUTICS
Oxford, United Kingdon, March 2, 2020
Celleron Therapeutics’ clinical trial initiated in China with partner Nuance Biotech
Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced that its partner in China, Nuance Biotech Ltd., initiated a Phase Ib/II study in Hong Kong to test CXD101 in patients suffering from peripheral T-cell lymphoma (PTCL), a rare type of blood cancer.
The study will start with a safety evaluation and pharmacokinetic study in Chinese patients in multiple tumour types, followed by a Phase II study in PTCL indication.(Read more)